S
Dagmar Rosa-Bjorkeson
VP, Respiratory Franchise, Novartis
SECRET TO SUCCESS: "It's the vision that I provide. I am strategic. I have passion and I care, so people will follow."
ROLE MODEL: Deborah Dunsire, who led Novartis' oncology business unit
Dagmar Rosa-Bjorkeson came by her global vision for pharma honestly: She grew up in Puerto Rico, studied chemistry and business in the States, joined Swiss-based Novartis, and later became general manager for Sweden.
Dagmar Rosa-Bjorkeson
Along the way, in 2001, she was tapped to head the launch of eczema drug Elidel—and like any self-respecting emerging leader, she ran with the challenge. "I aligned a whole launch team to deliver more than anybody thought the drug could do," she recalls. "That was a turning point in my career, because I had visibility at the global level."
A few promotions later, the new VP of Novartis' respiratory franchise is charged with growing the $700 million domestic market into a multi-billion dollar cash cow. But as a leader, Rosa-Bjorkeson (44) isn't only about results. "I want to create the best culture that supports a patient-centered focus with talented people who want to come to work every day—and I can pretty much guarantee the best results possible." It should come as no surprise that this mother of three describes herself as "big on quality of life." That's the kind of value one hopes will influence the next generation of leaders.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.